key: cord-0781044-2q7d5nqn
authors: Gernez, Yael; Murugesan, Kanagavel; Cortales, Cristina R.; Banaei, Niaz; Hoyte, Lisa; Pinsky, Benjamin A.; Lewis, David B.; Pham, Michele
title: Immunogenicity of a Third COVID-19 mRNA Vaccine Dose in PID Patients with Functional B-cell Defects
date: 2022-03-05
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2022.02.030
sha: 737859d03b3684a8f6d2f84642a6a317719df442
doc_id: 781044
cord_uid: 2q7d5nqn

nan

vaccines. This evaluation included using a receptor blocking activity competition assay that 45 evaluates the ability of the antibody in serum or plasma to bind to the spike protein receptor-46 binding domain (RBD) and prevent its interaction with the ACE2 cellular receptor, which 47 correlates with the antibody neutralization of viral infection (See repository methods). (2, 3) We 48 originally found that only two out of 35 patients with humoral defects (1 out of 15 CVID 49 patients) had an ACE2 blocking level of >50% and that such activity was undetectable in most of 50 these patients. These findings raised the possibility that two injections with mRNA vaccines may 51 leave patients with humoral defects with minimal protection from SARS-CoV-2 infection. quantity of spike protein-specific antibody has been reported to be significantly increased after a 56 third dose of SARS-CoV-2 mRNA vaccine in both adults aged >60 years and in patients with 57 kidney transplants. (5, 6) Notably, the ability of these antibodies to block the interaction of the 58 spike protein RBD with ACE2 was not evaluated. 59

Here, we report the humoral responses of PID patients after a third COVID-19 vaccine 60 (Table I) . We focused on the evaluation of efficacy of mRNA vaccination for PID patients with 61 humoral defects, including patients with moderately low to normal levels of B cells and impaired 62 or absent specific antibody responses. We excluded patients with absent B cells and globally not include any patients with hemophagocytic lymphohistiocytosis or autoinflammatory 65 conditions. Median age was 60.9 years and nighty two percent of our cohort were female. All 66 except one of the 14 patients were on immunoglobulin replacement therapy (Table 1 and To evaluate the immunogenicity of the vaccine, we measured the spike protein-specific 75 antibody response using a SARS-CoV-2 IgG antibody ELISA coating with S1 receptor binding 76 domain (RBD) antigen, (2) with reflex to SARS-CoV-2 ACE2 receptor blocking activity. (3) 77 These assays were performed at Stanford Health Care Clinical Virology Laboratory, a CLIA 78 certified laboratory (See repository methods). 79

All ten patients with CVID mounted an RBD IgG-specific antibody response and half 80 (N=5) had functional antibodies that had >50% ACE2 blocking activity. All four specific 81 antibody deficiency (SAD) or hypogammaglobulinemia patients mounted a positive RBD IgG-82 specific antibody response and had >50% ACE2 blocking activity. Overall, median ACE2 83 blocking activity increased from 2% to 79% in CVID patients (p=0.007; N=10; Wilcoxon 84 matched pairs test) and from 0% to 94.5% in patients with SAD or hypogammaglobulinemia the activity found after the second dose. These two results were repeated and/or reevaluated. No 88 variable was significantly associated with higher ACE2 blocking activity (age, gender, IgG at 89 baseline, CD4 and CD8 T cell count, absolute B cell count) (E 1). T cell function in our patient 90 population was normal as reflected by all having normal interferon gamma production after 91 mitogen stimulation. All except one had normal interferon production when stimulated with 92 antigen (SARS-CoV-2) ( Table E1) . 93

Our study of PID patients with functional B-cell defects is, to the best of our knowledge, 94 the first to evaluate the ACE2 receptor blocking activity after three doses of the SARS-CoV-2 95 mRNA vaccines in patients with PID. Based on results showing low ACE2 blocking activity 96 after two SARS-CoV-2 mRNA vaccine doses, immunity after two doses appears poor or 97 transient. In our cohort, most patients had an increase in ACE2 blocking activity with the most 98 significant change seen in patients with SAD or hypogammaglobulinemia. The median ACE2 99 blocking activity for this subgroup increased from 2% after two COVID-19 vaccine doses to 100 94.5% after the three doses. In the CVID group, where B-cell dysfunction is more severe, 101 median ACE2 blocking activity after three COVID-19 doses was 79%. These results show an 102 improvement and emphasize the recommendation for three doses of the SARS-CoV-2 mRNA 103 vaccines in patients with primary immunodeficiencies. Though improvement was seen in these 104 

CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in 134

Vaccinated Animals and Infected Patients

COVID-19 Vaccines for Moderately to Severely Immunocompromised 136 People

Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant 139

Recipients With Minimal Serologic Response to 2 Doses

Adults Aged >/=60 Years

This study has several limitations, including the relatively small size of our cohort and 111 the lack of healthy controls. Our study population was also predominantly female and older, with 112 a median age of 60.9 years. The threshold of ACE2 receptor blocking activity of >50% for a 113 positive result was chosen for this report but further studies are needed to further establish 114 reference ranges that denote protection. Testing was also performed a median of 4.8 weeks after 115 third dose and we plan to monitor longitudinally SARS-CoV-2 ACE2 receptor blocking activity 116 to assess the durability of this response. Nevertheless, our small study suggests that a third dose 117 of the SARS-CoV-2 mRNA vaccines seems to be beneficial in PID patients with CVID, SAD or 118 hypogammaglobulinemia and emphasizes the importance of testing the function of these 119 antibodies in this patient population.